Literature DB >> 29981816

EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Rama Soundararajan1, Anurag N Paranjape2, Sankar Maity3, Ana Aparicio3, Sendurai A Mani4.   

Abstract

Neuroendocrine/Aggressive Variant Prostate Cancers are lethal variants of the disease, with an aggressive clinical course and very short responses to conventional therapy. The age-adjusted incidence rate for this tumor sub-type has steadily increased over the past 20 years in the United States, with no reduction in the associated mortality rate. The molecular networks fueling its emergence and sustenance are still obscure; however, many factors have been associated with the onset and progression of neuroendocrine differentiation in clinically typical adenocarcinomas including loss of androgen-receptor expression and/or signaling, conventional therapy, and dysregulated cytokine function. "Tumor-plasticity" and the ability to dedifferentiate into alternate cell lineages are central to this process. Epithelial-to-mesenchymal (EMT) signaling pathways are major promoters of stem-cell properties in prostate tumor cells. In this review, we examine the contributions of EMT-induced cellular-plasticity and stem-cell signaling pathways to the progression of Neuroendocrine/Aggressive Variant Prostate Cancers in the light of potential therapeutic opportunities.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Neuroendocrine trans-differentiation; Plasticity; Variant prostate cancers

Mesh:

Year:  2018        PMID: 29981816      PMCID: PMC6496942          DOI: 10.1016/j.bbcan.2018.06.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  125 in total

1.  Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.

Authors:  N R Mucci; G Akdas; S Manely; M A Rubin
Journal:  Hum Pathol       Date:  2000-04       Impact factor: 3.466

2.  Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.

Authors:  Markus Germann; Antoinette Wetterwald; Natalia Guzmán-Ramirez; Gabri van der Pluijm; Zoran Culig; Marco G Cecchini; Elizabeth D Williams; George N Thalmann
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

3.  Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Authors:  Venkata Lokesh Battula; Kurt William Evans; Brett George Hollier; Yuexi Shi; Frank C Marini; Ayyakkannu Ayyanan; Rui-Yu Wang; Cathrin Brisken; Rudy Guerra; Michael Andreeff; Sendurai A Mani
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

Review 4.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

5.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Authors:  Min Zou; Roxanne Toivanen; Antonina Mitrofanova; Nicolas Floch; Sheida Hayati; Yanping Sun; Clémentine Le Magnen; Daniel Chester; Elahe A Mostaghel; Andrea Califano; Mark A Rubin; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Discov       Date:  2017-04-14       Impact factor: 39.397

6.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

Authors:  Etienne Dardenne; Himisha Beltran; Matteo Benelli; Kaitlyn Gayvert; Adeline Berger; Loredana Puca; Joanna Cyrta; Andrea Sboner; Zohal Noorzad; Theresa MacDonald; Cynthia Cheung; Ka Shing Yuen; Dong Gao; Yu Chen; Martin Eilers; Juan-Miguel Mosquera; Brian D Robinson; Olivier Elemento; Mark A Rubin; Francesca Demichelis; David S Rickman
Journal:  Cancer Cell       Date:  2016-10-10       Impact factor: 31.743

7.  Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.

Authors:  Haiyen E Zhau; Valerie Odero-Marah; Hui-Wen Lue; Takeo Nomura; Ruoxiang Wang; Gina Chu; Zhi-Ren Liu; Binhua P Zhou; Wen-Chin Huang; Leland W K Chung
Journal:  Clin Exp Metastasis       Date:  2008-06-06       Impact factor: 5.150

8.  Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells.

Authors:  Junyang Gong; JuneGoo Lee; Horiguchi Akio; Peter N Schlegel; Ruoqian Shen
Journal:  Endocrinology       Date:  2007-06-21       Impact factor: 4.736

9.  Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.

Authors:  C Berenguer; F Boudouresque; C Dussert; L Daniel; X Muracciole; M Grino; D Rossi; K Mabrouk; D Figarella-Branger; P-M Martin; L'Houcine Ouafik
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Authors:  Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

View more
  14 in total

Review 1.  The functional roles of exosomal long non-coding RNAs in cancer.

Authors:  Man Wang; Li Zhou; Fei Yu; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cell Mol Life Sci       Date:  2019-01-25       Impact factor: 9.261

Review 2.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.

Authors:  Plabon Kumar Das; Suja Pillai; Md Abdur Rakib; Jahan Ara Khanam; Vinod Gopalan; Alfred K Y Lam; Farhadul Islam
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

3.  Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13.

Authors:  Lin Chen; Weifeng Hu; Guohao Li; Yonglian Guo; Zhihua Wan; Jiajun Yu
Journal:  Cell Mol Biol Lett       Date:  2019-03-08       Impact factor: 5.787

Review 4.  Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression.

Authors:  Zheng Wang; Yicheng Zhao; Zhiqiang An; Wenliang Li
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

5.  Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.

Authors:  Baijun Dong; Juju Miao; Yanqing Wang; Wenqin Luo; Zhongzhong Ji; Huadong Lai; Man Zhang; Xiaomu Cheng; Jinming Wang; Yuxiang Fang; Helen He Zhu; Chee Wai Chua; Liancheng Fan; Yinjie Zhu; Jiahua Pan; Jia Wang; Wei Xue; Wei-Qiang Gao
Journal:  Commun Biol       Date:  2020-12-16

Review 6.  The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes.

Authors:  Ralf Hass; Juliane von der Ohe; Hendrik Ungefroren
Journal:  Cancers (Basel)       Date:  2020-12-07       Impact factor: 6.639

Review 7.  The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.

Authors:  Che-Yuan Hu; Kuan-Yu Wu; Tsung-Yen Lin; Chien-Chin Chen
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

8.  Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.

Authors:  Sara Hassan; Tony Blick; Jack Wood; Erik W Thompson; Elizabeth D Williams
Journal:  Front Cell Dev Biol       Date:  2022-04-13

Review 9.  Epigenetic mechanisms underlying prostate cancer radioresistance.

Authors:  Catarina Macedo-Silva; Rosaria Benedetti; Fortunato Ciardiello; Salvatore Cappabianca; Carmen Jerónimo; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2021-06-08       Impact factor: 6.551

10.  Isolation and Characterization of Two Novel Colorectal Cancer Cell Lines, Containing a Subpopulation with Potential Stem-Like Properties: Treatment Options by MYC/NMYC Inhibition.

Authors:  Jan Schulte Am Schulte Am Esch; Beatrice Ariane Windmöller; Johannes Hanewinkel; Jonathan Storm; Christine Förster; Ludwig Wilkens; Martin Krüger; Barbara Kaltschmidt; Christian Kaltschmidt
Journal:  Cancers (Basel)       Date:  2020-09-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.